That pattern is relevant well beyond incretin drugs
Who May Be Candidates and How to Proceed Safely with Your Provider Patients with long-standing remission, no stricture history, normal pancreatitis screening, and strong clinical indication for weight loss may be candidates for GLP-1 trial with heightened monitoring
We just dont know the long term implications of interfering with the GLP cascade during such a critical phase of development
Semaglutide is probably right for you if: You want the drug with the deepest long-term safety and cardiovascular outcomes data You have or are at high risk for cardiovascular disease (the SELECT trial data is specifically for this population) You've had significant GI issues with other medications and want to start conservatively You need something available today with a well-established clinical protocol Tirzepatide is probably right for you if: You've tried semaglutide and found the weight loss insufficient or plateaued You have insulin resistance or type 2 diabetes and want better glycemic control alongside weight loss You have metabolic-associated steatohepatitis (fatty liver disease) the MASH data is compelling You want better-than-semaglutide weight loss with a Phase 3-validated profile Retatrutide is probably right for you if: You're comfortable being an early adopter and understand you're working with Phase 2 data You have severe obesity (BMI over 40) and haven't achieved sufficient results with GLP-1 or dual agonists You have significant hepatic steatosis or high triglycerides where glucagon activity may add direct benefit You're enrolled through a supervised clinical program that can monitor the novel aspects of triple agonism One more note: none of these drugs are right for you without lab work first
A review of case reports (Franks et al., 2012) further heightened concerns about the potential adverse effects of GLP-1RAs on the pancreas, resulting in elevated pancreatic enzymes and AP
Specifically, it acts as an agonist (activator) for the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor
